^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT3 mutation + MLL mutation

    i
    Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2, HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Met
    Entrez ID:
    2322
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy. (PubMed, Blood)
    In summary, we show that expression of immunotargets in pediatric AML differs from known expression profiles in adult AML. We identify CLEC12A/CD33 as preferential generic combinatorial immunotargets in pediatric AML and CD33/FLT3 as immunotargets specific for KMT2A mutated infant AML.
    Clinical • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD33 (CD33 Molecule) • CD34 (CD34 molecule)
    |
    CD33 positive • FLT3 overexpression • MLL mutation • FLT3 mutation + MLL mutation
    over3years
    Analysis of Genomic Landscape in Patients with Acute Myeloid Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    At least one mutation is observed in more than 90% patients. On average, more than 2 mutated genes per patient are identified. Some gene mutations are associated with gene rearrangement.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NPM1 (Nucleophosmin 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • FLT3-ITD mutation • NPM1 mutation • KIT mutation • TET2 mutation • MLL rearrangement • CEBPA mutation • JAK2 V617F • MLL mutation • FLT3 mutation + MLL mutation • NPM1 mutation + NRAS mutation
    over3years
    [VIRTUAL] Driver mutations in pediatric core binding factor acute myeloid leukemia (ESHG 2020)
    Mutational profiling revealed characteristic differences in spectrum and frequency of somatic mutations in patients with t(8;21) and inv(16). Novel mutations, which may be involved in leukemia development, were identified. The work was supported by the Russian Science Foundation (grant # 18−15-00398).
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • ASXL1 (ASXL Transcriptional Regulator 1) • CBL (Cbl proto-oncogene) • KDM6A (Lysine Demethylase 6A)
    |
    KRAS mutation • NRAS mutation • KIT mutation • CBL mutation • MLL mutation • FLT3 mutation + MLL mutation • KIT exon 8 mutation